Drug policy: The year in review, and the year ahead

Rachel SachsRachel Sachs, associate professor of law


Last year was an unquestionably busy time for health care news of all kinds. Media and policy coverage rightly focused on the many attempts to repeal the Affordable Care Act, but it was also an eventful year in news for those of us who focus on prescription drug policy. In this post, I review five of the biggest drug policy developments of the past year, and look ahead to five issues I expect to make headlines in 2018.

Like 2017, drug policy watchers should expect 2018 to be a year full of interesting news. Here’s hoping it is also a year for policymakers to find solutions to some of the many challenges in drug policy.

Read the full piece at Health Affairs.

Leave a Comment

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.